


NEWPORT PHASE III DRUGS MODULE

INTELLIGENCE ON PRODUCTS STILL IN PHASE III CLINICAL TRIALS



WHAT PHASE III DRUGS CAN HELP YOU DO

- Conduct better, earlier product targeting
- Monitor the competition
- Seek out partners earlier
- Anticipate line extensions for launched products
- Predict the strategies innovators will use to protect their franchise

HOW YOU BENEFIT

- Monthly intelligence updates
- Simple web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

HOW TO SUBSCRIBE

The *Newport Phase III Drugs Module* is an optional subscription module that may be added on a per-seat basis to *Newport Premium™* (for Generics) or *Newport Global™* (for Generics) product configurations for an additional annual charge.

A subscription to a base system is required before purchasing this module. To get a quotation, contact your account manager or visit

science.thomsonreuters.com/info/sales

THOMSON REUTERS REGIONAL OFFICES

North America

Philadelphia +1 855 260 5607
+1 215 386 0100

Latin America

+55 11 8370 9845

Europe, Middle East and Africa

London +0800 145 6412

Asia Pacific

Singapore +65 6775 5088
Tokyo +81 3 5218 6500

For a complete office list visit: science.thomsonreuters.com/contact

LS 201207 SPEC NP3DF5

Copyright © 2012 Thomson Reuters

In today's hyper-competitive pharmaceutical industry, generic companies and API manufacturers need every advantage they can get over their rivals.

GAIN A COMPETITIVE EDGE BY TARGETING PRODUCTS EARLIER

The *Newport Phase III Drugs Module* enables you to target new development opportunities as soon as possible.

Seamlessly integrated into *Newport Global™* and *Newport Premium™*, *Phase III Drugs* extends the base system's coverage of APIs to include more than 400 compounds in late-stage development (Phase III clinical, registration or under review).

It includes patent, synthesis, and clinical development details for these late-stage compounds, equipping you to begin your targeting and competitive tracking processes earlier than ever before.

For pharmaceutical products that are already in the market, *Phase III Drugs* adds information about further clinical trials taking place, giving you insights into the possible line extensions or additional indications that are being pursued in different markets.

Two dedicated searches enable you to identify development-stage products by exacting criteria. You can review a launched drug's complete development history and receive email alerts as new drugs progress through the development pipeline.

PHASE III DRUGS HELPS YOUR STRATEGIC PLANNING TEAM TO:

- Identify opportunities that match your strategic needs and strengths years before launch
- Adjust your research timing, priorities, and resources based on competitive intelligence for products from Phase III through pre-launch
- Anticipate line-extensions for products in the market and strategies for protecting franchises

PHASE III DRUGS HELPS YOUR BUSINESS DEVELOPMENT TEAM TO:

- Profile candidate products for acquisition, alliances, licensing, or supply and manufacturing
- Track and monitor patenting and clinical trial activities for products of interest
- Evaluate candidate products against the earliest competitive intelligence

PHASE III DRUGS HELPS YOUR PRODUCT INTELLIGENCE TEAM TO:

- View regulatory filings, such as US DMFs, for products still in Phase III clinical trials
- Explore chemical structure diagrams and routes of synthesis with patent and literature references
- Uncover additional indications being pursued for drugs in the marketplace

PHASE III DRUGS ALSO AIDS COMPANY AND PATENT INTELLIGENCE

The *Newport Phase III Drugs Module* can help your company intelligence team to monitor development portfolios of hundreds of companies, including for line extensions for launched products. It can also help your patent intelligence team to explore worldwide patent families and individual patents for products in Phase III clinical trials, pre-registration, registration, and pre-launch phases.

Development Programs		
Development Program Name	Highest Development Program Status	Development Therapy Area
APA-01 + atorvastatin (atherosclerosis), Phosphagenics	Discovery	Atherosclerosis
atorvastatin	Launched	Alzheimers disease, At Hyperlipidemia
atorvastatin + amlodipine	Launched	Angina, Atherosclerosis Hyperlipidemia, Hypertension
atorvastatin + losartan (time-delayed, hypertension/ hyperlipidemia), Hanall/ Yuhon	Discovery	Hyperlipidemia, Hypertension
ezetimibe + atorvastatin, Schering-Plough/Merck & Co	Phase 3 Clinical	Hypercholesterolemia
fenofibrate + atorvastatin (oral, MeltDose, hypercholesterolemia), LifeCycle	Phase 2 Clinical	Hypercholesterolemia, Hyperlipidemia
largipitant + extended-release nicotinic acid + atorvastatin (lipid metabolism disorder), Merck & Co	Discovery	Lipid metabolism disorder
torcetrapib + atorvastatin	Discontinued	Atherosclerosis, Hyperlipidemia

© 2003 - 2009 THOMSON REUTERS

For both launched and Phase III drugs, get a snapshot of which additional development programs are being pursued and what status has been reached.



THOMSON REUTERS™